Agile 3+ and Agile 4 scores are accurate to detect advanced metabolic dysfunction-associated steatotic liver disease

Read full text
Authors: Muriel Manica, Luis Fernando Ferreira, Cristiane A. Villela-Nogueira, Edison Roberto Parise, Nathalie C. Leite, Ana C.F. Cardoso, Ana L.F. de Azevedo, Nilma L.S. Ruffeil, Cristiane V. Tovo
Cited by: 2
References: 26

Abstract

BACKGROUND: The prognosis of metabolic dysfunction-associated steatotic liver disease (MASLD) is related to the presence of liver fibrosis (LF). The Agile 3+ and Agile 4 scores are proposed as noninvasive methods to identify advanced LF and cirrhosis, respectively, associating vibration-controlled transient elastography (VCTE) with clinical and laboratorial data. AIM: To evaluate the performance of Agile scores in the assessment of LF in MASLD patients. METHODS: This is a cross-sectional multicentric study conducted at three gastroenterology/hepatology outpatient units from Brazil, including individuals with biopsy-proven MASLD. To calculate the Agile 3+ and Agile 4 scores for the evaluation of advanced fibrosis (F≥3) and cirrhosis (F4), respectively, the formula proposed by Sanyal et al . was applied. RESULTS: A total of 220 patients were included, mostly women ( n = 146; 66%) and with diabetes ( n = 136; 61.5%). The prevalence of advanced fibrosis and cirrhosis was 21.82% ( n = 48) and 9.55% ( n = 21), respectively. There was a strong correlation between Agile 3+ ( r = 0.751) and VCTE ( r = 0.729) with the LF stage evaluated by liver biopsy, while the correlation of Agile 4 was moderate ( r = 0.535). However, the Agile 3+ and Agile 4 scores have shown high sensitivity and specificity (higher than 80% in all cases) when compared to liver biopsy. Also, there was significance in the area under the ROC curve, which was inferior than 0.5 for all cases. CONCLUSION: A good correlation was confirmed between the Agile scores and VCTE with the stages of fibrosis in MASLD individuals, classifying correctly the presence of LF and cirrhosis better than VCTE solo, with a smaller indeterminate zone.

Fields of Study & Subjects

Liver Disease Diagnosis and Treatment GDF15 and Related Biomarkers Clusterin in disease pathology

Publication details

Journal / source
European Journal of Gastroenterology & Hepatology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Volume
38
Issue
4
Pages
487–492
Publication date
25 February 2026
Language
EN